ArticleFrontiers in oncology2026
TSPAN32 as a biomarker associated with radiotherapy and immune microenvironment remodeling in lung adenocarcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lung cancer is a high-mortality-rate malignant tumor. Radiotherapy combined with immunotherapy shows great potential in improving patient survival. This study aims to identify gene sets associated with radiotherapy effectiveness and immune infiltration in lung adenocarcinoma (LUAD), construct a prognostic model, and preliminarily evaluate the effectiveness of the key gene TSPAN32 as a predictive diagnostic marker and therapeutic target for LUAD. Methods: Genomic datasets from The Cancer Genome Atlas (TCGA) were analyzed to develop a 12-gene risk score model. The prognostic value of TSPAN32 was assessed, and its correlation with immune infiltration was examined. Results: The 12-gene risk score model accurately predicts prognosis and correlates with immune infiltration. TSPAN32, with high weight in the model, can independently predict prognosis and is associated with immune infiltration. TSPAN32 is significantly downregulated in LUAD cells. Its overexpression significantly inhibits the proliferation and migration of A549 and H1299 cells, enhances radiosensitivity, and may exert biological effects through the TSPAN32-PTEN signaling axis. Discussion: These findings suggest that TSPAN32 could serve as a predictive biomarker for LUAD patients who may benefit from combined radiotherapy and immunotherapy, providing a theoretical basis for optimizing treatment strategies and improving patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.